Trials / Unknown
UnknownNCT05786963
Comparison of Hepatus and FibroScan for Evaluation of Fibrosis and Steatosis
Comparison of Hepatus and FibroScan for Evaluation of Fibrosis and Steatosis in Chronic Hepatitis B or NAFLD Patients
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 400 (estimated)
- Sponsor
- Beijing Friendship Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Totals of 400 chronic hepatitis B or non-alcoholic fatty liver disease (NAFLD) patients with or without cirrhosis will be enrolled. Patients' clinical characteristics, including alanine aminotransferase, aspartic aminotransferase, total bilirubin, direct bilirubin, indirect bilirubin, triglyceride and total cholesterol, hepatitis B surface antigen, steatosis, and liver stiffness measurement will be collected. The consistence of liver fibrosis and steatosis assessment between Hepatus and FibroScan will be evaluated in this study.
Conditions
Timeline
- Start date
- 2022-12-29
- Primary completion
- 2023-12-01
- Completion
- 2024-04-01
- First posted
- 2023-03-28
- Last updated
- 2023-03-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05786963. Inclusion in this directory is not an endorsement.